# A Clinical Trial Evaluating the Safety, Tolerability, and Preliminary Efficacy of HCL001 Cell Injection (Homologous Allogeneic Hepatocytes) in Patients With Decompensated Cirrhosis

> **NCT06306781** · NA · NOT_YET_RECRUITING · sponsor: **RenJi Hospital** · enrollment: 18 (estimated)

## Conditions studied

- Decompensated Cirrhosis

## Interventions

- **DRUG:** HCL001 cell (homologous allogeneic hepatocytes) injection

## Key facts

- **NCT ID:** NCT06306781
- **Lead sponsor:** RenJi Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-03-30
- **Primary completion:** 2026-07-30
- **Final completion:** 2026-12-30
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2024-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06306781

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06306781, "A Clinical Trial Evaluating the Safety, Tolerability, and Preliminary Efficacy of HCL001 Cell Injection (Homologous Allogeneic Hepatocytes) in Patients With Decompensated Cirrhosis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06306781. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*